Suzhou Yimufeng Biotechnology

Suzhou Yimufeng Biotechnology is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the development of next-generation cell therapies. The company utilizes a proprietary non-viral transposon-based gene modification platform to create CAR-T and TCR-T cell products, aiming to provide safer and more affordable treatments compared to traditional viral-based methods. Yimufeng's lead candidate, YMF-001, is a CD19-targeted CAR-T therapy currently being evaluated in clinical trials for B-cell malignancies and autoimmune diseases such as systemic lupus erythematosus. By leveraging its innovative platform, the company seeks to overcome the manufacturing complexities and high costs associated with cell therapy. Yimufeng is also expanding its research into solid tumor indications to address significant unmet medical needs in oncology.